C24-Ceramide
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


C24-Ceramide
Description:
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer[1][2][3].UNSPSC:
12352211Hazard Statement:
H302, H315, H319, H335Target:
MTORType:
Reference compoundRelated Pathways:
PI3K/Akt/mTORField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/c24-ceramide.htmlPurity:
99.92Solubility:
DMSO : < 1 mg/mL (ultrasonic; warming) |Ethanol : 25 mg/mL (ultrasonic) |THF : 25 mg/mL (ultrasonic)Smiles:
CCCCCCCCCCCCCCCCCCCCCCCC (N[C@@H] (CO) [C@H] (O) /C=C/CCCCCCCCCCCCC) =OMolecular Formula:
C42H83NO3Molecular Weight:
650.11Precautions:
H302, H315, H319, H335References & Citations:
[1]Ventura AE, et al. Lipid domain formation and membrane shaping by C24-ceramide. Biochim Biophys Acta Biomembr. 2020 Oct 1;1862 (10) :183400.|[2]Lee JH, et al. C24 Ceramide Lipid Nanoparticles for Skin Wound Healing. Pharmaceutics. 2025 Feb 12;17 (2) :242.|[3]Zhang Y, et al. C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation. Hepatology. 2021 Feb;73 (2) :692-712.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedCAS Number:
34435-05-7
